Registration of the meeting of Aspen representatives with representatives of MZ SR, on 17.09.2015 at 10.00 am. at MZ SR

For MZ SR:

• director-General Department of Pharmacy and Drug Policy MUDr. Adam Hlôška
• director of the Department of Classification, Pricing and Drug Policy PharmDr. Rastislav Pullmann
• officer of the Department of Classification, Pricing and Drug Policy of MVDr. Erika Hanzelyová

For Aspen:

• director General of RNDr. Iva Váchová
• director-General Aspen Central Europe Wojciech Sulimierski
• JUDr. Marko Polakovič

The meeting took place at the request of Aspen.

The meeting was opened by the Director General of the Department of Pharmacy and Drug Policy Dr. Adam Hlôška.

For Aspen:

Aspen following a meeting at the Ministry held on 20.08.2015, re-mapping and analysing the entire drug situation in detail Fragiparine and Fragiparine forte on the Slovak market. The company has enormous interest in making medicines primarily available to Slovaks patients. The company carried out an intensive analysis and again found that the delivery of both of these medicines to the Slovak market is sufficient to cover patient consumption. To the same the findings are based on data from the NCZI and health insurance companies; and Ministry.

For MZ SR:

Slovakia is part of the EU and free movement of goods applies here. SCHOOL can prohibit the export of medicinal products only in accordance with current legislation of the Slovak Republic and EU. Ministry wondered what conclusions the company had reached and what steps it had taken.

For Aspen:

Aspen has started more since the last meeting at the Ministry communicate with all the distribution components, and thanks to this they recorded a decrease in complaints about the unavailability of the above medicines.

For MZ SR:

The Ministry recommends that Aspen communicates sufficiently with all distribution companies with which they have contracts.

The sitting was closed by the Director-General of the Department of Pharmacy and Drug Policy Dr. Adam Hlôška.